Cargando…

Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)

BACKGROUND: To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level. METHODS: In this population-based study, we included individuals wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moccia, Marcello, Loperto, Ilaria, Lanzillo, Roberta, Capacchione, Antonio, Carotenuto, Antonio, Triassi, Maria, Brescia Morra, Vincenzo, Palladino, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448448/
https://www.ncbi.nlm.nih.gov/pubmed/32847587
http://dx.doi.org/10.1186/s12913-020-05664-x
_version_ 1783574500301864960
author Moccia, Marcello
Loperto, Ilaria
Lanzillo, Roberta
Capacchione, Antonio
Carotenuto, Antonio
Triassi, Maria
Brescia Morra, Vincenzo
Palladino, Raffaele
author_facet Moccia, Marcello
Loperto, Ilaria
Lanzillo, Roberta
Capacchione, Antonio
Carotenuto, Antonio
Triassi, Maria
Brescia Morra, Vincenzo
Palladino, Raffaele
author_sort Moccia, Marcello
collection PubMed
description BACKGROUND: To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level. METHODS: In this population-based study, we included individuals with MS living in the Campania Region of Italy from 2015 to 2017, on treatment with intramuscular Interferon Beta-1a (Avonex® = 618), subcutaneous pegylated Interferon Beta-1a (Plegridy® = 259), subcutaneous Interferon Beta-1a (Rebif® = 1220), and subcutaneous Interferon Beta-1b (Betaferon® = 348; and Extavia® = 69). We recorded healthcare resource utilisation from administrative databases (hospital discharges, drug prescriptions, MS-related outpatients), and derived costs from the Regional formulary. We classified hospital admissions into MS-related and non-MS-related. Persistence (time to switch to other disease modifying treatments (DMTs)), and adherence (medication possession ratio (MPR) = medication supply obtained/medication supply expected during follow-up period) were calculated. RESULTS: Patients treated with Rebif® were younger, when compared with other Interferon Beta formulations (p < 0.01). The probability of switching to other DMTs was 60% higher for Betaferon®, 90% higher for Extavia®, and 110% higher for Plegridy®, when compared with Rebif® (p < 0.01). Plegridy® presented with 7% higher adherence (p < 0.01), and Betaferon® with 3% lower adherence (p = 0.03), when compared with Rebif®. The probability of MS-related hospital admissions was 40% higher in Avonex® (p = 0.03), 400% higher in Betaferon® (p < 0.01), and 60% higher in Plegridy® (p = 0.04), resulting into higher non-DMT-related costs, when compared with Rebif®. DISCUSSION: Interferon Beta formulations presented with different prescription patterns, persistence, adherence, healthcare resource utilisation and costs, with Rebif® being used in younger patients and with less MS-related hospital admissions.
format Online
Article
Text
id pubmed-7448448
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74484482020-08-27 Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) Moccia, Marcello Loperto, Ilaria Lanzillo, Roberta Capacchione, Antonio Carotenuto, Antonio Triassi, Maria Brescia Morra, Vincenzo Palladino, Raffaele BMC Health Serv Res Research Article BACKGROUND: To differentiate five formulations of Interferon Beta for the treatment of multiple sclerosis (MS) in clinical practice, by analysing persistence, adherence, healthcare resource utilisation and costs at population level. METHODS: In this population-based study, we included individuals with MS living in the Campania Region of Italy from 2015 to 2017, on treatment with intramuscular Interferon Beta-1a (Avonex® = 618), subcutaneous pegylated Interferon Beta-1a (Plegridy® = 259), subcutaneous Interferon Beta-1a (Rebif® = 1220), and subcutaneous Interferon Beta-1b (Betaferon® = 348; and Extavia® = 69). We recorded healthcare resource utilisation from administrative databases (hospital discharges, drug prescriptions, MS-related outpatients), and derived costs from the Regional formulary. We classified hospital admissions into MS-related and non-MS-related. Persistence (time to switch to other disease modifying treatments (DMTs)), and adherence (medication possession ratio (MPR) = medication supply obtained/medication supply expected during follow-up period) were calculated. RESULTS: Patients treated with Rebif® were younger, when compared with other Interferon Beta formulations (p < 0.01). The probability of switching to other DMTs was 60% higher for Betaferon®, 90% higher for Extavia®, and 110% higher for Plegridy®, when compared with Rebif® (p < 0.01). Plegridy® presented with 7% higher adherence (p < 0.01), and Betaferon® with 3% lower adherence (p = 0.03), when compared with Rebif®. The probability of MS-related hospital admissions was 40% higher in Avonex® (p = 0.03), 400% higher in Betaferon® (p < 0.01), and 60% higher in Plegridy® (p = 0.04), resulting into higher non-DMT-related costs, when compared with Rebif®. DISCUSSION: Interferon Beta formulations presented with different prescription patterns, persistence, adherence, healthcare resource utilisation and costs, with Rebif® being used in younger patients and with less MS-related hospital admissions. BioMed Central 2020-08-26 /pmc/articles/PMC7448448/ /pubmed/32847587 http://dx.doi.org/10.1186/s12913-020-05664-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Moccia, Marcello
Loperto, Ilaria
Lanzillo, Roberta
Capacchione, Antonio
Carotenuto, Antonio
Triassi, Maria
Brescia Morra, Vincenzo
Palladino, Raffaele
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
title Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
title_full Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
title_fullStr Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
title_full_unstemmed Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
title_short Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy)
title_sort persistence, adherence, healthcare resource utilisation and costs for interferon beta in multiple sclerosis: a population-based study in the campania region (southern italy)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448448/
https://www.ncbi.nlm.nih.gov/pubmed/32847587
http://dx.doi.org/10.1186/s12913-020-05664-x
work_keys_str_mv AT mocciamarcello persistenceadherencehealthcareresourceutilisationandcostsforinterferonbetainmultiplesclerosisapopulationbasedstudyinthecampaniaregionsouthernitaly
AT lopertoilaria persistenceadherencehealthcareresourceutilisationandcostsforinterferonbetainmultiplesclerosisapopulationbasedstudyinthecampaniaregionsouthernitaly
AT lanzilloroberta persistenceadherencehealthcareresourceutilisationandcostsforinterferonbetainmultiplesclerosisapopulationbasedstudyinthecampaniaregionsouthernitaly
AT capacchioneantonio persistenceadherencehealthcareresourceutilisationandcostsforinterferonbetainmultiplesclerosisapopulationbasedstudyinthecampaniaregionsouthernitaly
AT carotenutoantonio persistenceadherencehealthcareresourceutilisationandcostsforinterferonbetainmultiplesclerosisapopulationbasedstudyinthecampaniaregionsouthernitaly
AT triassimaria persistenceadherencehealthcareresourceutilisationandcostsforinterferonbetainmultiplesclerosisapopulationbasedstudyinthecampaniaregionsouthernitaly
AT bresciamorravincenzo persistenceadherencehealthcareresourceutilisationandcostsforinterferonbetainmultiplesclerosisapopulationbasedstudyinthecampaniaregionsouthernitaly
AT palladinoraffaele persistenceadherencehealthcareresourceutilisationandcostsforinterferonbetainmultiplesclerosisapopulationbasedstudyinthecampaniaregionsouthernitaly